EcoDrugPlus

Alk Receptor Tyrosine Kinase

Ensembl ID : ENSBSLG00000024187
Gene Symbol: ALK
2 Cross references
194 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 1

Ensembl ID : ENSBSLG00000003936
Gene Symbol: ABCC1
3 Cross references
203 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSBSLG00000008173
Gene Symbol: ABCC8
3 Cross references
227 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Alpha

Ensembl ID : ENSBSLG00000013651
Gene Symbol: ATP4A
3 Cross references
183 Possible Orthologues:

Atpase H+/k+ Transporting Subunit Beta

Ensembl ID : ENSBSLG00000004558
Gene Symbol: ATP4B
3 Cross references
171 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Alpha 1

Ensembl ID : ENSBSLG00000000739
Gene Symbol: ATP1A1
3 Cross references
270 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSBSLG00000003535
Gene Symbol: ATP1B1
3 Cross references
216 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSBSLG00000003135
Gene Symbol: ATP1B2
3 Cross references
189 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSBSLG00000026684
Gene Symbol: AXL
2 Cross references
188 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSBSLG00000021285
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

B1 Bradykinin Receptor-Like

Ensembl ID : ENSBSLG00000023877
Gene Symbol: LOC114848729
3 Cross references
149 Possible Orthologues:

B2 Bradykinin Receptor-Like

Ensembl ID : ENSBSLG00000023902
Gene Symbol: LOC114849009
2 Cross references
241 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).